Avinger, Inc. Announces Fourth Quarter and Full Year 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Avinger, Inc. Announces Fourth Quarter and Full Year 2014 Results

REDWOOD CITY, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (Nasdaq: AVGR ) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported financial results for the fourth quarter and year ended December 31, 2014.

Recent Highlights

  • Completed enrollment in VISION, a 133-patient clinical trial designed to evaluate the safety and efficacy of Pantheris™, Avinger's image-guided atherectomy device, which allows physicians to precisely remove arterial plaque in PAD patients.
  • Completed an initial public offering of five million shares on January 29, 2015, raising net proceeds of approximately $56.8 million.
  • Added seven new lumivascular accounts in the fourth quarter, expanding the installed base of the Company's lumivascular platform to 60 accounts.
  • Appointed Jeff Soinski as the Company's new President and Chief Executive Officer, succeeding Avinger's founder John B. Simpson, Ph.D., M.D., who continues as Executive Chairman.
  • Strengthened the Board of Directors with the additions of two healthcare business and technology leaders, James G. Cullen and Thomas J. Fogarty, M.D.

"As announced today, we have achieved a significant clinical milestone for our Company with the completion of patient enrollment in the VISION trial for our Pantheris image-guided atherectomy device. Based on the currently available data, we believe we are on track to meet or exceed the primary safety and efficacy endpoint requirements," said Jeff Soinski, President and Chief Executive Officer. "We are at an exciting point in the Company's history, as the confluence of our novel lumivascular platform technology, a capable and proven management team, and a compelling market opportunity positions us to dramatically improve the way vascular disease is treated. We believe Pantheris can significantly penetrate the well-established $1 billion PAD market, and we see a clear pathway to expand this underserved market.

"Entering 2015, our foundation is strong, and we are looking ahead to an exciting year. A primary objective is filing our 510(k) application for Pantheris in the second half of the year, after six month follow-up data is available. On a commercial basis, we are focused on increasing the installed base of customers using our currently available lumivascular products and expanding our sales force and marketing infrastructure in anticipation of the Pantheris commercial launch in 2016," concluded Soinski.

Full Year 2014 Financial Results

Total revenue was $11.2 million for the year ended December 31, 2014, compared to $13.0 million in 2013. The decrease in total revenue in 2014 was related to strategic decisions made by the Company in the fourth quarter of 2013 to focus commercial efforts on its lumivascular programs to broaden physician exposure to optical coherence tomography (OCT) image interpretation, build the installed base of the Lightbox™ imaging console, and reduce cash consumption prior to Pantheris availability. Related to these objectives, Avinger reduced the size of its sales force by approximately 50% from its peak and restructured several of its internal resources to focus on the lumivascular opportunity. Although this re-alignment resulted in an overall revenue reduction attributable to a 49% decrease in non-imaging catheter sales, it produced a 37% increase in Lightbox imaging console sales. At the same time, it provided a 23% improvement in sales force productivity and a 29% decrease in operating expenses.

Revenues for 2014 from the Company's disposable devices were $7.3 million, and revenues associated with the Company's Lightbox imaging console were $3.9 million.

Gross margin for the year ended December 31, 2014 increased to 42%, compared to 37% for the year ended December 31, 2013. This increase was primarily attributable to the increase in sales of the Company's higher margin lumivascular platform products, as well as a decrease in manufacturing infrastructure-related expenses during the second half of 2013.

Operating expenses for 2014 were $29.7 million, a decrease of 29% compared to $41.7 million for 2013. The decrease in operating expenses was primarily attributable to the reduction in personnel-related expenses, outside services and product development materials and related costs, as the Company focused its research and development efforts on its lumivascular platform products, particularly Pantheris.

Loss from operations for 2014 was $25.0 million, compared to $37.0 million for 2013. Adjusted EBITDA, a non-GAAP measure, was a loss of $22.9 million for 2014 as compared to a loss of $34.8 million for 2013.

Cash, cash equivalents and short-term investments totaled $12.3 million as of December 31, 2014. On January 29, 2015, the Company completed an initial public offering, which raised net proceeds of approximately $56.8 million, after deducting underwriting discounts and commissions and offering expenses.

Fourth Quarter Financial Results

Total revenue was $3.1 million for the fourth quarter ended December 31, 2014, a decrease of 9% from $3.4 million in the comparable 2013 period. Fourth quarter 2014 revenues from the Company's disposable devices were $1.5 million, while revenues associated with the Company's Lightbox imaging console were $1.6 million.

Gross margin for the fourth quarter of 2014 was 49%, up from 31% in the comparable quarter in 2013.

Operating expenses for the fourth quarter of 2014 were $8.5 million, consistent with the fourth quarter of 2013.

Loss from operations for the fourth quarter of 2014 was $7.0 million, compared to $7.4 million for the fourth quarter of 2013. Adjusted EBITDA, a non-GAAP measure, was a loss of $6.5 million for the fourth quarter of 2014, compared to a $6.9 million loss for the fourth quarter of 2013.

Financial Outlook for 2015

The Company expects 2015 revenue to be in the range of $12 to $14 million, which represents year-over-year growth ranging from 7% to 25%.

Adjusted EBITDA for 2015 is expected to be a loss of $31 to $33 million, representing an increase of 35% to 44% over 2014, as the Company invests in the development of its lumivascular platform and expansion of its commercial infrastructure.

Conference Call

Avinger will hold a conference call today, March 12, at 1:30pm PT/4:30pm ET to discuss its fourth quarter and 2014 results. Individuals may listen to the call by dialing (855) 638-4817 for domestic callers or (262) 912-6051 for international callers, referencing Conference ID: 90291483. To listen to a live webcast, please visit the investor relations section of Avinger's website at: www.avinger.com .

A replay of the call will be available beginning March 12, 2015 at 4:30pm PT/7:30pm ET through midnight on March 13, 2015. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 90291483. The webcast will also be available on Avinger's website for one year following the completion of the call.

About Avinger, Inc.

Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral arterial disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The Company's mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its lumivascular platform, the only intravascular image-guided system available in this market. Avinger's current lumivascular products include the Lightbox™ imaging console and Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs. The Company is also developing Pantheris™, an image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. Pantheris is currently undergoing a U.S. clinical trial intended to support a 510(k) submission to the FDA in the second half of 2015. For more information, please visit the Company's website at www.avinger.com .

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the market opportunity for our products, progress towards achieving clinical endpoints and planned regulatory and commercialization activities. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; ability to demonstrate the benefits of our lumivascular platform; the resource requirements related to Pantheris, which has not been approved and may not be approved; the outcome of clinical trial results including our VISION clinical trial; potential exposure to third-party product liability and intellectual property litigation; lack of long-term data demonstrating the safety and efficacy of our lumivascular platform products; reliance on third-party vendors; dependency on physician adoption; reliance on key personnel; and requirements to obtain regulatory approval to commercialize our products; as well as the other risks described in the section entitled "Risk Factors" in the company's 424(B)(4) filing made with the Securities and Exchange Commission on January 30, 2015 in connection with the company's initial public offering. These forward-looking statements speak only as of the date hereof. Avinger disclaims any obligation to update these forward-looking statements.

Use of Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures in this release. Management of the company believes that these non-GAAP financial measures, considered together with GAAP financial information, provide useful information for investors by excluding certain non-cash and other income and expense that are not indicative of the company's core operating performance. Reconciliations of the non-GAAP financial measures used in this release to the most directly comparable GAAP measures for the respective periods can be found in "Reconciliation of GAAP to Non-GAAP Financial Information" immediately following the financial tables. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.

Avinger, Inc.
Statements of Operations Data
(in thousands, except per share data)
(unaudited)
 
  Three Months Ended Year Ended
  December 31, December 31,
  2014 2013 2014 2013
         
         
Revenues  $ 3,073  $ 3,395  $ 11,213  $ 12,964
Cost of revenues  1,571  2,344  6,513  8,205
Gross profit  1,502  1,051  4,700  4,759
         
Operating expenses:        
Research and development  2,874  3,309  11,224  15,973
Selling, general and administrative  5,603  5,180  18,503  25,758
Total operating expenses  8,477  8,489  29,727  41,731
Loss from operations  (6,975)  (7,438)  (25,027)  (36,972)
         
Interest income  1  1  2  11
Interest expense  (1,112)  (1,160)  (6,016)  (2,934)
Other income (expense), net  (72)  (6)  (909)  5
Loss before provision for income taxes  (8,158)  (8,603)  (31,950)  (39,890)
Provision (benefit) for income taxes  (23)  (2)  14  11
Net loss  $ (8,135)  $ (8,601)  $ (31,964)  $ (39,901)
         
Net loss per share, basic and diluted  $ (33.62)  $ (36.14)  $ (132.63)  $ (170.52)
         
Weighted average common shares        
used to compute net loss        
per share, basic and diluted  242  238  241  234
         
Avinger, Inc.
Balance Sheets Data
(in thousands)
(unaudited)
 
   As of December 31,
  2014 2013
Assets    
Current assets:    
Cash and cash equivalents  $ 12,316  $ 12,221
Accounts receivable, net  2,068  1,627
Inventories  3,991  4,741
Prepaid expenses and other current assets  562  1,011
Total current assets  18,937  19,600
     
Property and equipment, net  2,608  4,858
Other assets  3,235  550
Total assets  $ 24,780  $ 25,008
     
Liabilities, convertible preferred stock and stockholders' deficit    
Current liabilities:    
Accounts payable  $ 1,013  $ 996
Accrued compensation  1,147  1,274
Accrued expenses and other current liabilities  4,850  1,456
Total current liabilities  7,010  3,726
     
Long-term borrowings  20,410  20,052
Convertible notes and accrued interest  8,643  13,731
Other long-term liablities  325  627
Total liabilities  36,388  38,136
     
Convertible preferred stock  132,260  99,654
Stockholders' deficit:    
Common stock  --   -- 
Additional paid-in capital  2,665  1,787
Accumulated deficit  (146,533)  (114,569)
Total stockholders' deficit  (143,868)  (112,782)
Total liabilities, convertible preferred stock, and stockholders' deficit  $ 24,780  $ 25,008
 
Reconciliation of GAAP to Non-GAAP Financial Information
 
Avinger, Inc.
Adjusted EBITDA
(in thousands)
(unaudited)
 
  Three Months Ended Year Ended
  December 31, December 31,
  2014 2013 2014 2013
         
Loss from operations  $ (6,975)  $ (7,438)  $ (25,027)  $ (36,972)
Add: Stock-based compensation  132  142  641  654
Add: Depreciation and amortization  319  420  1,451  1,501
Adjusted EBITDA  $ (6,524)  $ (6,876)  $ (22,935)  $ (34,817)

INVESTOR CONTACT Leigh Salvo (415) 513-1281 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 109

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 109

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 97

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading

Top 5 Most Recently Viewed Articles

Arcline Investment Management Sells Resolution Medical to Resonetics

Updated Category News Views 213

Arcline Investment Management Sells Resolution Medical Arcline Investment Management, a dynamic private equity firm, has made a notable move in the medical technology landscape. The firm is set to sell its portfolio company, Resolution Medical, to Resonetics. This strategic decision highlights Arcline's ongoing commitment to advancing innovative solutions within the...

Continue Reading
Cheetah Mobile Surges with Impressive Q2 Financial Results

Updated Category News Views 223

Cheetah Mobile Reports Strong Growth in Q2 2025 Cheetah Mobile Inc. (NYSE: CMCM), a prominent IT company, has recently reported its financial results for the second quarter of 2025. The results indicate a remarkable increase in total revenue and profitability, showcasing the company’s ongoing strategic transformation. Management Insights on Performance Mr. Sheng Fu,...

Continue Reading
OwlTing Group Launches OwlPay Harbor for Enhanced Payment Solutions

Updated Category News Views 287

OwlTing Group Transforms Payments with AI-Powered OwlPay Harbor OwlTing Group, a pioneering blockchain fintech firm, has announced a significant evolution of its payment platform, OwlPay Harbor. This innovative service integrates artificial intelligence to enhance the experience for developers and users alike, making financial transactions faster and more secure than ever...

Continue Reading
Colt DCS Taps Nguyen for CEO Amid Growth Surge

Updated Category News Views 24

Nguyen Takes Helm at Colt DCS Well, here's a move that'll definitely shake the data center landscape a bit: Quy Nguyen's stepping up as the Chief Executive Officer at Colt Data Centre Services. From temporary to permanent, that decision speaks volumes about the trust in his leadership acumen during these transformative times. Colt's apparently betting the farm on Nguyen...

Continue Reading
NWR Storage Containers Expands with New Facility Opening

Updated Category News Views 143

NWR Storage Containers Expands with New Facility Opening NWR Storage Containers, a prominent provider of storage container rentals, is excited to announce its relocation to a larger facility. This event marks a significant step forward in their journey of growth and commitment to serving customers effectively. Relocation to a New Facility The newly established operations...

Continue Reading